Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LSTA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Eltrapuldencel-T | Stage IV Melanoma | Phase 3 · NCT01875653 | Terminated |
| Cell | Chronic Myocardial Ischemia | Phase 3 · NCT01508910 | Completed |
| Therapeutic Autologous Dendritic Cells | Melanoma (Skin) | Phase 1/2 · NCT00012064 | Completed |
| SOC | Critical Limb Ischemia | Phase 2 · NCT02501018 | Completed |
| Carmustine Implant | Brain and Central Nervous System Tumors | Phase 2 · NCT00814593 | Withdrawn |
| Autologous Bone Marrow-derived… | ST Segment Elevation Myocardial Infarction | Phase 2 · NCT01495364 | Completed |
| Nab-paclitaxel | Pancreas Cancer | Phase 1/2 · NCT06592664 | Withdrawn |
| Lymphokine-Activated Killer Cells | Brain and Central Nervous System Tumors | Phase 2 · NCT00814593 | Withdrawn |
| CLBS16 | Coronary Microvascular Dysfunction | Phase 2 · NCT04614467 | Terminated |
| Hematopoietic Progenitor Cell Antigen CD34 | Critical Limb Ischemia | Phase 2 · NCT02501018 | Completed |
| CLBS03 High Dose | Diabetes Mellitus | Phase 2 · NCT02691247 | Completed |
| Certepetide | Cholangiocarcinoma | Phase 2 · NCT05712356 | Completed |
| CLBS201 | Chronic Kidney Diseases | Phase 1 · NCT04990427 | Completed |
| CLBS119 | Covid-19 | Phase 1 · NCT04522817 | Withdrawn |
| Internalized-arginylglycylaspartic Acid Cyclic… | Pancreatic Cancer | Phase 1 · NCT03517176 | Completed |
| Biological Challenge Agent | Kidney Cancer | Phase 1 · NCT00014131 | Terminated |
Also used in these trials (approved or third-party drugs, not LSTA's own candidates): Autologous PBMCs in GM-CSF, Gemcitabine Hydrochloride, Oxaliplatin, Durvalumab, Cisplatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LSTA holds $19.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.9M/quarter from operations, an estimated runway of 20.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
After evaluating the conditions described above in the aggregate, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LSTA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Branham Justin Earl | 5%+ holder (13G) | 462,149 | 4.28% | 2026-08-21 |
| David J Mazzo President & CEO, Director · +127,000 options |
Insider | 311,890 | 2.89% | 2026-01-09 |
| Mohammad Azab Director |
Insider | 104,925 | 0.97% | 2026-01-09 |
| Steven M Klosk Director |
Insider | 95,815 | 0.89% | 2026-01-09 |
| Gregory B Brown Director |
Insider | 95,659 | 0.89% | 2026-01-09 |
| Cynthia Louise Flowers Director |
Insider | 95,446 | 0.88% | 2026-01-09 |
| Kristen K Buck EVP, R&D and CMO · +40,000 options |
Insider | 93,462 | 0.87% | 2026-01-09 |
| Heidi Henson Director |
Insider | 85,725 | 0.79% | 2026-01-09 |
| Tariq Imam SVP, Bus Dev, General Counsel · +7,000 options |
Insider | 36,078 | 0.33% | 2026-01-09 |
| James Nisco SVP, Fin/Treas, Chief Actg Off · +14,000 options |
Insider | 32,311 | 0.30% | 2026-01-09 |
| Joshua Lehrer-Graiwer President & COO |
Insider | 27,808 | 0.26% | 2026-09-17 |
| Ted W Love Director |
Insider | 19,260 | 0.18% | 2026-09-17 |
Share count 10,804,066 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LSTA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →